87 results about "Triple-Negative Breast Carcinoma" patented technology

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and / or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

Provided is a compound useful as a prophylactic and / or therapeutic agent for bladder cancer.As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and / or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and / or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and / or therapeutic agent for mutant FGFR3-positive bladder cancer.

The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer.

The invention provides a fluorescence labeled human triple-negative breast cancer osseous metastasis cell line. The fluorescence labeled human triple-negative breast cancer osseous metastasis cell line is prepared with a method as follows: a human triple-negative breast cancer cell MDA-MB-231 is cultured; a lentivirus carrier containing RFP (red fluorescence protein) is amplified, and an RFP labelled MDA-MB-231 cell is prepared; the RFP-MDA-MB-231 cell is transplanted to the fourth pair breast fat pad position of a nude mouse and grows into tumor; shin bone of a hind limb is taken after 4-6 weeks, bone marrow is flushed with a buffer solution and digested with collagenase, a single cell from the bone marrow is obtained, in-vitro culture amplification is performed, and red fluorescence cells are sorted with a flow cytometry; through tumor formation screening in a body of the nude mouse, the red fluorescence labelled MDA-MB-231 human triple-negative breast cancer osseous metastasis cellline is obtained. The human triple-negative breast cancer osseous metastasis cell line has the characteristics of osseous metastasis, is labelled by fluorescent protein and realizes visualization andtraceability.

The structural general formula of the novel Base-imidazole derivative is shown as any one of the following formulas, and the novel Base-imidazole derivative is prepared from p-bromoaniline, paraformaldehyde, n-butyllithium, phenanthrenequinone / biphenyl formyl / acenaphthenequinone and substituted aniline through cyclization and coupling reaction. The novel Base-imidazole derivative provided by the invention emits blue light, has obvious aggregation-induced emission and solid-state emission, has good thermal stability, meets the basic requirements of device materials, and has certain applicationpotential. Part of the novel Base-imidazole derivatives have a good inhibition effect on one or two of triple-negative breast cancer cells and liver cancer cells, and have low toxicity to normal cells; part of the novel Base-imidazole derivatives can inhibit one or more of non-small cell lung cancer cells, triple negative breast cancer cells and lung cancer cells to a certain extent.

The invention relates to a physical method for selectively containing the malignant degree of triple negative breast cancer cells. The physical method is characterized in that firstly, low-temperature normal-pressure helium plasmas are utilized to treat a culture medium to activate the culture medium, so that the culture medium carries with a large number of effective active substances; and then the breast cancer cells can be killed by means of the method that the active substances interact with the breast cancer cells through the treated culture medium, so that the effect on containing of the malignant degree of the triple negative breast cancer cells is achieved. According to the physical method for selectively containing the malignant degree of the triple negative breast cancer cells, the low-temperature normal-pressure helium plasmas are adopted so that the culture medium can generate the appropriate active oxygen substances, the containing effect on the triple negative breast cancer cells is achieved, and nearly no influence on normal cells is generated, so that high selectivity is achieved; and the breast cancer cells are treated through the indirect physical method, the convenient and efficient characteristics are achieved, and a culture medium solution subjected to plasma treatment can be treated as medical injection liquid to conduct injection therapy on breast cancer patients. According to the physical method, the triple negative breast cancer cells are safely, painlessly and efficiently killed without side effects.

The invention discloses a marker for detecting triple negative breast cancer as well as a detection reagent and application thereof, and relates to the technical field of tumor detection. By detecting the expression level of at least one marker of ZEB1-AS1, TMEM254-AS1, LINC01087, LINC01122 and LINC00856 and utilizing differentiated expression of the markers in triple negative breast cancer tissue and para-carcinoma tissue of the triple negative breast cancer tissue, the marker can be used for diagnosis, prognosis evaluation or drug screening of the triple negative breast cancer.

The invention discloses a molecular structure and a synthesis method of a new triple negative breast cancer drug. The molecular structure is pHLIP (Var7)-P1AP, wherein pHLIP (Var7)-AEEQNPWARYLEWLFPTETLLLELC and P1AP-CKKSRALF are synthesized by the steps of 1) synthesizing a pHLIP (Var7) Cys polypeptide sequence through a solid-phase polypeptide synthesis method: AEEQNPWARYLEWLFPTETLLLELC; 2) synthesizing a Cys P1AP polypeptide sequence through a solid-phase polypeptide synthesis method: CKKSRALF; and 3) enabling the pHLIP (Var7) Cys to be connected with the Cys P1AP through a disulfide bond toobtain the pHLIP (Var7)-P1AP sequence: AEEQNPWARYLEWLFPTETLLLELC-CKKSRALF. The C end of the pHLIP (Var7)-P1AP can be specifically inserted into triple negative breast cancer cells, the disulfide bondcracks to release P1AP to tumor cells, and P1AP can be targeted to the internal parts of tumor cell PAR1 recipient cells to achieve the purpose of inhibiting tumor cell proliferation.

The invention discloses an artificially synthesized anticancer peptide and an acid responsive nanoparticle precursor thereof. The nanoparticle is formed by connecting an anti-cancer peptide and an amphiphilic monomethyl polyethylene glycol-polypropylene glycol polymer through an acid-responsive chemical bond. Tests prove that the anti-cancer peptide can kill tumor cells through membrane rupture activity, and has the advantages of excellent broad-spectrum anti-cancer activity and drug resistance. The nanoparticles are selectively sensitive to a tumor subacid environment, can completely release anti-cancer peptides, and play an active role of a targeted tumor cell line. And the polypeptide has the advantages of hemolysis resistance, high plasma stability, low in-vivo systemic toxicity, systemic drug delivery and the like. The nanoparticle has a remarkable inhibition effect on various tumor cells including triple negative breast cancer, and particularly has a relatively good clinical application potential on drug-resistant triple negative breast cancer.